C. Kent Osborne

43.0k total citations · 10 hit papers
173 papers, 25.4k citations indexed

About

C. Kent Osborne is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, C. Kent Osborne has authored 173 papers receiving a total of 25.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 77 papers in Genetics and 57 papers in Molecular Biology. Recurrent topics in C. Kent Osborne's work include HER2/EGFR in Cancer Research (76 papers), Estrogen and related hormone effects (71 papers) and Breast Cancer Treatment Studies (37 papers). C. Kent Osborne is often cited by papers focused on HER2/EGFR in Cancer Research (76 papers), Estrogen and related hormone effects (71 papers) and Breast Cancer Treatment Studies (37 papers). C. Kent Osborne collaborates with scholars based in United States, United Kingdom and Italy. C. Kent Osborne's co-authors include Rachel Schiff, Gary M. Clark, D. Craig Allred, Richard Elledge, Susan G. Hilsenbeck, Carlos L. Arteaga, Grazia Arpino, Gary C. Chamness, Suzanne A.W. Fuqua and Jennet Harvey and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

C. Kent Osborne

169 papers receiving 24.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

1999 1.6k citations Jennet Harvey, Gary M. Clark et al. Journal of Clinical Oncology profile →
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

2008 1.4k citations Jian Huang, Carolina Gutiérrez et al. profile →
Tamoxifen in the Treatment of Breast Cancer

1998 1.0k citations C. Kent Osborne profile →
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

2014 936 citations Matthew D. Burstein, Anna Tsimelzon et al. Clinical Cancer Research profile →
Mechanisms of Endocrine Resistance in Breast Cancer

2010 877 citations C. Kent Osborne, Rachel Schiff Annual Review of Medicine profile →
Treatment of HER2-positive breast cancer: current status and future perspectives

2011 696 citations Carlos L. Arteaga, C. Kent Osborne et al. Nature Reviews Clinical Oncology profile →
Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

1993 683 citations D. Craig Allred, Gary M. Clark et al. profile →
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

2003 642 citations C. Kent Osborne, Gary C. Chamness et al. profile →
The value of estrogen and progesterone receptors in the treatment of breast cancer

1980 579 citations C. Kent Osborne, William McGuire et al. profile →
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

2003 565 citations Richard Elledge, C. Kent Osborne et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Kent Osborne United States	79	14.8k	10.7k	8.8k	8.7k	4.0k	173	25.4k
John A. Foekens Netherlands	79	11.4k 0.8×	13.5k 1.3×	10.6k 1.2×	3.3k 0.4×	3.6k 0.9×	337	25.5k
Robert I. Nicholson United Kingdom	74	9.4k 0.6×	8.1k 0.8×	4.3k 0.5×	4.9k 0.6×	2.9k 0.7×	262	18.4k
Lars A. Akslen Norway	67	14.0k 1.0×	13.8k 1.3×	11.6k 1.3×	3.3k 0.4×	4.4k 1.1×	314	29.1k
Edith A. Perez United States	79	20.7k 1.4×	6.6k 0.6×	11.1k 1.3×	4.4k 0.5×	5.8k 1.5×	400	30.1k
J.F.R. Robertson United Kingdom	64	8.7k 0.6×	4.8k 0.4×	5.7k 0.7×	5.0k 0.6×	4.2k 1.1×	258	15.3k
Carlos L. Arteaga United States	101	18.4k 1.2×	19.8k 1.8×	6.4k 0.7×	2.9k 0.3×	7.2k 1.8×	432	34.7k
John M.S. Bartlett United Kingdom	60	10.5k 0.7×	6.2k 0.6×	7.0k 0.8×	2.7k 0.3×	3.7k 0.9×	310	18.8k
Robert L. Sutherland Australia	78	7.8k 0.5×	10.4k 1.0×	3.8k 0.4×	5.0k 0.6×	3.3k 0.8×	236	19.2k
Anne‐Lise Børresen‐Dale Norway	65	10.9k 0.7×	14.8k 1.4×	12.4k 1.4×	4.5k 0.5×	3.0k 0.7×	190	26.0k
Suzanne A.W. Fuqua United States	69	6.4k 0.4×	9.3k 0.9×	4.0k 0.5×	6.6k 0.8×	1.8k 0.5×	203	16.6k

Countries citing papers authored by C. Kent Osborne

Since Specialization

Citations

This map shows the geographic impact of C. Kent Osborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Kent Osborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Kent Osborne more than expected).

Fields of papers citing papers by C. Kent Osborne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Kent Osborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Kent Osborne. The network helps show where C. Kent Osborne may publish in the future.

Co-authorship network of co-authors of C. Kent Osborne

This figure shows the co-authorship network connecting the top 25 collaborators of C. Kent Osborne. A scholar is included among the top collaborators of C. Kent Osborne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Kent Osborne. C. Kent Osborne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Woodward, Wendy A., William E. Barlow, Reshma Jagsi, et al.. (2020). Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology. 6(4). 505–505. 50 indexed citations

Rimawi, Mothaffar F., Polly Niravath, Tao Wang, et al.. (2019). TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 26(4). 821–827. 34 indexed citations

Guarducci, Cristina, Martina Bonechi, Matteo Benelli, et al.. (2018). Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. npj Breast Cancer. 4(1). 38–38. 86 indexed citations

Veeraraghavan, Jamunarani, Carmine De Angelis, Jorge S. Reis‐Filho, et al.. (2017). De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. The Breast. 34. S19–S26. 41 indexed citations

Malorni, Luca, Mario Giuliano, Ilenia Migliaccio, et al.. (2016). Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research. 14(5). 470–481. 31 indexed citations

Hollander, Petra den, Anna Tsimelzon, Jonathan H. Shepherd, et al.. (2016). Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research. 76(7). 1942–1953. 70 indexed citations

Rimawi, Mothaffar F., Rachel Schiff, & C. Kent Osborne. (2015). Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine. 66(1). 111–128. 208 indexed citations

Morrison, Gladys, Xiaoyong Fu, Martin J. Shea, et al.. (2014). Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Research and Treatment. 144(2). 263–272. 39 indexed citations

Burstein, Matthew D., Anna Tsimelzon, Graham M. Poage, et al.. (2014). Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research. 21(7). 1688–1698. 936 indexed citations breakdown →

10.

Fu, Xiaoyong, C. Kent Osborne, & Rachel Schiff. (2013). Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. The Breast. 22. S12–S18. 64 indexed citations

11.

Rimawi, Mothaffar F. & C. Kent Osborne. (2012). Blocking both driver and escape pathways improves outcomes. Nature Reviews Clinical Oncology. 9(3). 133–134. 8 indexed citations

12.

Wang, Yen-Chao, Gladys Morrison, Ryan Gillihan, et al.. (2011). Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Research. 13(6). R121–R121. 213 indexed citations

13.

Dave, Bhuvanesh, Ilenia Migliaccio, Maya Gutierrez, et al.. (2010). Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers. Journal of Clinical Oncology. 29(2). 166–173. 190 indexed citations

14.

Massarweh, Suleiman, C. Kent Osborne, Chad J. Creighton, et al.. (2008). Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research. 68(3). 826–833. 375 indexed citations

15.

Creighton, Chad J., Suleiman Massarweh, Shixia Huang, et al.. (2008). Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research. 68(18). 7493–7501. 101 indexed citations

16.

Wang, Lihua, Xiao Yang, Xiaohu Zhang, et al.. (2006). Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 10(6). 487–499. 60 indexed citations

17.

Harvey, Jennet, Gary M. Clark, C. Kent Osborne, & D. Craig Allred. (1999). Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology. 17(5). 1474–1474. 1630 indexed citations breakdown →

18.

Ciocca, Daniel R., Richard Elledge, Gary M. Clark, et al.. (1998). Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).. PubMed. 4(5). 1263–6. 38 indexed citations

19.

Allred, D. Craig, Gary M. Clark, Rafael Molina, et al.. (1992). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology. 23(9). 974–979. 329 indexed citations

20.

Brünner, Nils, C. Kent Osborne, & Mogens Spang‐Thomsen. (1987). Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Research and Treatment. 10(3). 229–242. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact